Search Results

NUTF2 在 HNSCC 患者中的表达及与预后关系分析.

• Authors : 靳书滨¹; 刘晓燕²; 耿文华¹

• Source: Journal of Kunming Medical University / Kunming Yike Daxue Xuebao. 2025, Vol. 46 Issue 6, p103-110. 8p.

Record details

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)

• Authors : Merck Sharp & Dohme LLC

• Source: TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With

Record details

CD40 Agonist and PD-1 Inhibitor in HNSCC

• Source: Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients With Resectable HPV-negative Mucosal Head/Neck Squamous Cell Carcinoma (

Record details

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

• Authors : Xingchen Peng, PhD, Professor

• Source: A Prospective Randomized Controlled Trial Comparing Low-Dose Radiotherapy Combined With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone as Neoadjuvant Therapy in

Record details

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC (LONG'E)

• Authors : Keymed Biosciences Co.Ltd; Sinocelltech Ltd.

• Source: The Safety and Efficacy of Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, a Phase Ib Study

Record details

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

• Authors : Merck Sharp & Dohme LLC; Kartik Sehgal, MD, Principal Investigator

• Source: A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma

Record details

Radiotherapy is enhanced by CPH:SA IL-1α microparticles in a murine HNSCC tumor model.

• Authors : Hasibuzzaman, M. M.^1,2,3 (AUTHOR); He, Rui⁴ (AUTHOR); Khan, Ishrat Nourin^1,2,3 (AUTHOR)

• Source: BMC Cancer. 4/1/2025, Vol. 25 Issue 1, p1-11. 11p.

Record details

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

• Source: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With

Record details

Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

• Authors : Qilu Pharmaceutical Co., Ltd.

• Source: A Prospective, Single-Arm Clinical Trial of Iparomlimab and Tuvonralimab Combined With Spatially Fractionated Radiotherapy and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky Head and

Record details

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

• Authors : Turnstone Biologics, Corp.

• Source: A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head

Record details